Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Sleep, Insomnia

In brief

The broad objective of this investigation is to assess the safety and efficacy of oral therapy with dexmedetomidine for the induction and maintenance of restful sleep.

Key facts

Study ID

NCT02818569

Run by

Massachusetts General Hospital

People needed

15

Starts

2016-10-01

Expected to finish

2018-06-01

Last updated by the study team

2019-10-02

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age between 18-50
• Native English speaking
• ASA physical status classification P1 and P2 (stable chronic condition)
• Normal body habitus.

You may not qualify if…

• Abnormal sleep habits
• Sleeping less than 5 hours each night
• Going to sleep before 9:00 PM or after 2:00 AM on a regular basis
• Waking up before 5:00 AM or after 10:00 AM on a regular basis.
• Takes medication that alters sleep, cognitive function, or both. -Has a history of a known neurological or psychiatric problem.
• Younger than 18 or older than 50 years of age.
• Known or suspected sleep disorder(s).

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.